✦ LIBER ✦

Considerations in the Rational Design and Conduct of Phase I/II Pediatric Clinical Trials: Avoiding the Problems and Pitfalls

✍ Scribed by Abdel-Rahman, S M; Reed, M D; Wells, T G; Kearns, G L

Book ID: 110020006
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 241 KB
Volume: 81
Category: Article
ISSN: 0009-9236
DOI: 10.1038/sj.clpt.6100134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Statistical considerations in the design

Statistical considerations in the design, conduct and analyses of antiemetic clinical trials

✍ G. R. Morrow; Enzo Ballatori; Susan Groshen; Ian Olver 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 30 KB

The conduct of phase I-II clinical trial

The conduct of phase I-II clinical trials in children with cancer

✍ Pratt, Charles B. 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 677 KB

Phase I Clinical Trials in children with cancer are carried out with therapeutic intent, so as to define antileukemic/antitumor activity, dose-limiting toxicity, maximum tolerated dosage, and pharmacokinetics. These studies define a dosage of an agent or combination that may be used in a larger stud

Recent reminders of why the gold standar

Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial

✍ Maurie Markman 📂 Article 📅 2004 🏛 Current Science Inc. 🌐 English ⚖ 55 KB

On the Importance of Accounting for Comp

On the Importance of Accounting for Competing Risks in Pediatric Cancer Trials Designed to Delay or Avoid Radiotherapy: I. Basic Concepts and First Analyses

✍ Bee-Choo Tai; Richard G. Grundy; David Machin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Recombinant human anti–transforming grow

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place